Seres Therapeutics, Inc. 8-K

What Happened Seres Therapeutics, Inc. (MCRB) announced in an 8-K filed July 8, 2026 that its reconvened 2026 Annual Meeting of Stockholders approved an amendment and restatement of the Seres Therapeutics, Inc. 2025 Incentive Award Plan (the “2025 Plan”) to increase the number of shares available for issuance under the plan by 900,000 shares. The Board of Directors had previously approved the amendment on April 22, 2026, subject to stockholder approval, and the proxy describing the proposal was filed on April 27, 2026.

Key Details

• Stockholder approval granted at the reconvened 2026 Annual Meeting (the meeting had been adjourned from June 9, 2026).
• Increase to the 2025 Plan: 900,000 additional shares of common stock authorized for issuance.
• Board approval: April 22, 2026; definitive proxy filed April 27, 2026.
• The amended and restated 2025 Plan text is filed as Exhibit 10.1 to the 8-K.

Why It Matters The amendment expands the pool of shares available for equity awards—used for employee, officer and director compensation—so Seres can grant additional stock-based incentives going forward. For investors, this is material because it enables future equity grants that can support hiring and retention but also represents potential dilution to existing shareholders if and when awards are issued. The amendment became effective upon the stockholder vote reported in this filing.